1. Y.F. Shealy, J.A. Montgomery and W.R. Laster Jr., Antitumor activity of triazenoimidazoles, Biochem. Pharmacol. 11; 674 (1962).
2. J. Heyes, Antimetastatic effect of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-methylimidazole, J. Natl. Cancer Inst. 53: 279 (1974).
3. T. Giraldi, P. J. Houghton, D. M. Taylor and C. Nisi, Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice, Cancer Treat. Rep. 62: 721 (1978).
4. T. Giraldi, G. Sava, R. Cuman, C. Nisi and L. Lassiani, Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt, (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane, and cyclophosphamide in mice bearing Lewis lung carcinoma, Cancer Res. 41: 2524 (1981).
5. G. Sava, T. Giraldi, L. Lassiani and C. Nisi, Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma, Cancer Res. 44: 64 (1984).